Journal profile · ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
ISSN 2214-6237 · Elsevier · United States
Journal of Clinical and Translational Endocrinology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.9 (journal website); fully open access; APC about USD 3,570; median 98 days to acceptance (76 articles, last 24 months); 44 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Journal of Clinical and Translational Endocrinology is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins and Cystic Fibrosis Research Advances, together about 25.9% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
The focus of the open access Journal of Clinical and Translational Endocrinology is patient-oriented research in a variety of disciplines in endocrinology, including diabetes, metabolic bone disease and osteoporosis, thyroid disease, pituitary and lipid disorders. High-priority areas include novel pilot/proof-of-concept clinical trials in humans and basic science research involving human specimens.Case studies should be submitted to Journal of Clinical and Translational Endocrinology?s open access companion title, Journal of Clinical and Translational Endocrinology: Case Reports .
From the journal's Aims & Scope
Research area (LetPub): ENDOCRINOLOGY & METABOLISM
Editor-in-chief Trang LePublisher website
Editorial board by country: none in mainland China; most named United States 23, Italy 4, South Korea 3, Thailand 2, Saudi Arabia 1 (33 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Management and ResearchMedicine10.1%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine8.4%
- Cystic Fibrosis Research AdvancesMedicine7.4%
- Diabetes Management and EducationMedicine6.9%
- Diabetes Treatment and ManagementMedicine6.3%
- Thyroid Disorders and TreatmentsMedicine6.1%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology6.1%
- Vitamin D Research StudiesMedicine5.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 4.9Publisher website ·
- CiteScore 2026-06
- 5.8LetPub ·
- CiteScore (publisher)
- 5.8Publisher website ·
- SJR 2026-06
- 1.06LetPub ·
- SNIP 2026-06
- 1.06LetPub ·
- h-index
- 42OpenAlex ·
- i10-index
- 219OpenAlex ·
- 2-year mean citedness
- 4.43OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 39LetPub ·
Articles by year OpenAlex count · 449 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 27 | 27 | 6 |
| 2025 | 44 | 44 | 63 |
| 2024 | 51 | 51 | 471 |
| 2023 | 17 | 17 | 117 |
| 2022 | 19 | 19 | 158 |
| 2021 | 43 | 43 | 803 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
98 daysMedian, submission to acceptance · P25–P75 68 days – 143 days
- Acceptance to online
- median 2 days (76 articles)
- Submission to online
- median 100 days
- Sample
- 76 articles with submission and acceptance dates (82 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 47 daysPublisher website ·
- Submission to acceptance
- 93 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,570 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 3,500 / EUR 3,270 / GBP 2,800 / JPY 434,110 | — | — | |
| LetPub | USD 2,650 | Yes | — | |
| Publisher website | USD 3,570 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Abstract
- ≤ 250 words
- Cover letter
- Required
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United States
- Language
- English
- ISSN
- 2214-6237
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Clinical and Translational Endocrinology
What CAS zone is Journal of Clinical and Translational Endocrinology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Clinical and Translational Endocrinology is in Zone 3 of Medicine, and in Zone 3 of the minor category Endocrinology & Metabolism. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Clinical and Translational Endocrinology?
The journal's website gives an impact factor of 4.9; this is the journal's own figure, as LetPub lists none for it; CiteScore 5.8, h-index 42.
How long does peer review take at Journal of Clinical and Translational Endocrinology?
Based on the dates recorded on 76 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 98 days (interquartile range 68–143 days); authors report an average review time of about 16 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Clinical and Translational Endocrinology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Clinical and Translational Endocrinology based?
Of the 33 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (23), Italy (4) and South Korea (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Clinical and Translational Endocrinology?
According to LetPub and DOAJ records, Journal of Clinical and Translational Endocrinology is indexed in ESCI, Scopus and DOAJ.
Is Journal of Clinical and Translational Endocrinology open access, and what is the APC?
Journal of Clinical and Translational Endocrinology is a fully open-access journal. APC about USD 3,570.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .